Breast Cancer | Specialty

PARP Inhibitors Arrive for BRCA+ Breast Cancer

March 11th 2018

The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.

Dual Targeting Advances in HER2+/HR+ Breast Cancer

March 11th 2018

The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.

Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs

March 10th 2018

Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.

Dr. King Discusses Approaches to Lymphedema in Breast Cancer

March 10th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses approaches to treating lymphedema in patients with breast cancer.

Dr. Robson on Exploratory Analysis From OlympiAD in Breast Cancer

March 9th 2018

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Frontline Palbociclib Effective Regardless of Prior Treatment in Breast Cancer Subgroups

March 9th 2018

Palbociclib (Ibrance) demonstrated significant efficacy in combination with letrozole (Femara) in the frontline setting of estrogen receptor-positive, HER2-negative, postmenopausal metastatic breast cancer.

Dr. Andre on Questions With Immunotherapy in Triple-Negative Breast Cancer

March 9th 2018

Fabrice André, MD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the remaining questions with immunotherapy agents as potential therapy for patients with triple-negative breast cancer. Andre expanded on this in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

Dr. Gradishar on Using Genetic Testing to Identify Actionable Results in Breast Cancer

March 9th 2018

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the utilization of genetic testing in breast cancer to identify actionable results for patients.

Ribociclib Active Across Premenopausal Breast Cancer Subgroups

March 9th 2018

The progression-free survival benefit for ribociclib in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer was sustained across patient subgroups, according to findings from the phase III MONALEESA-7 trial.

Olaparib Breast Cancer Efficacy Highlighted in Added Analyses

March 8th 2018

Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer

March 8th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.

Dr. Isaacs Discusses Antibody Drug Conjugates in TNBC

March 1st 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.

Dr. Finn on the FDA Approval of Frontline Abemaciclib in HR+/HER2- Breast Cancer

February 27th 2018

Richard S. Finn, an associate professor of medicine at the Geffen School of Medicine at the University of California, Los Angeles, discusses the FDA approval of abemaciclib (Verzenio) for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.

FDA Approves Frontline Abemaciclib for HR+/HER2- Advanced Breast Cancer

February 27th 2018

The FDA has approved abemaciclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Adjuvant Chemo Benefit Sustained in ER-Negative, Locally Recurrent Breast Cancer

February 22nd 2018

The survival benefit with adjuvant chemotherapy in ER-negative breast cancer patients with isolated locoregional recurrence was sustained in the final analysis of the phase III CALOR trial.

Liquid Biopsy Demonstrates Prognostic Potential in Metastatic TNBC

February 21st 2018

Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.

Take-Home Messages on Breast Oncology Advances

February 17th 2018

Immunotherapy for Triple-Negative Breast Cancer

February 17th 2018

PARP Inhibitors for BRCA-Mutated TNBC

February 17th 2018

Advantages with Nab-Paclitaxel in TNBC

February 17th 2018